Comparing the efficacy and safety of first-line treatments for chronic lymphocytic leukemia: a network meta-analysis
Tailored chemotherapy-free regimens can be selected based on age, comorbidities, IGHV status, and cytogenetic abnormalities to optimize treatment outcomes while considering different adverse events spectra.
Authors
- Katherine Steiner (ORCID: https://orcid.org/0000-0002-5022-0736)
- Guang-Yi Sun (ORCID: https://orcid.org/0000-0003-3379-4209)
- Tingyu Wen (ORCID: https://orcid.org/0000-0002-6431-4362)
- Wenxin Jiang (ORCID: https://orcid.org/0009-0008-6315-3721)
- Suzannah Bridge (ORCID: https://orcid.org/0009-0003-9836-9200)
- Peng Liu (ORCID: https://orcid.org/0000-0001-6129-6325)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- University of Oxford (GB)
- National Cancer Center (US)
- National Clinical Research (US)
- Bodle Technologies (United Kingdom) (GB)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1093/jnci/djae245
- Citations
- 3
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.31
Funders
- National Natural Science Foundation of China